VEGF/DLL4 BINDING AGENTS AND USES THEREOF
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human D...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French |
Published |
28.03.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
La présente invention concerne des agents de liaison à VEGF, des agents de liaison à DLL4, des agents de liaison bispécifiques à VEGF/DLL4, et des procédés d'utilisation des agents pour le traitement de maladies telles que le cancer. La présente invention concerne des anticorps qui se lient spécifiquement au VEGF humain, des anticorps qui se lient spécifiquement au DLL4 humain et des anticorps bispécifiques qui se lient spécifiquement au VEGF humain et/ou au DLL4 humain. La présente invention concerne en outre des procédés d'utilisation des agents pour inhiber la croissance tumorale. L'invention concerne également des méthodes de traitement du cancer qui comportent l'administration d'une quantité thérapeutiquement efficace d'un agent ou d'un anticorps selon la présente invention à un patient souffrant d'une tumeur ou d'un cancer. |
---|---|
Bibliography: | Application Number: WO2012US56886 |